Patients with platinum-resistant ovarian , fallopian tube or primary peritoneal cancer were randomised @ : @ to receive @-week cycles of weekly paclitaxel ( wPxl ; @ mg/m ( @ ) / week @ with @-week break ) plus saracatinib ( S ; @ mg o.d. ) or placebo ( P ) continuously , starting @ week before wPxl , until disease progression .